Indonesia Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Indonesia Breast Cancer Therapeutics Market Analysis

$ 3999

The Indonesia breast cancer therapeutics market is expected to grow from $109 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The breast cancer therapeutics market growth drivers in Indonesia are the growing prevalence of breast cancer and increasing research and development activities in breast cancer therapeutics. The market is segmented by therapy, by cancer type, and by distribution channel. Sanbe Pharma, Biocon, and Merck & Co. Inc. are leading companies in Indonesia's breast cancer therapeutics market.

ID: IN10IDPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Parul Choudhary

Buy Now

Indonesia Breast Cancer Therapeutics Market Executive Analysis

The Indonesia breast cancer therapeutics market size is at around $109 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. In the draft of the 2022 state budget, the Indonesian government allocated $17 Bn, or 9.4% of the total planned state expenditures of $180 Bn, to the health sector. The COVID-19 pandemic, health system reforms, the stunting rate reduction, and the sustainability of the National Health Insurance Program, also known as "Jaminan Kesehatan Nasional (JKN)," will all be covered by the health budget. Due to the opportunities offered by Indonesia's long-term economic growth potential and its insufficient public healthcare infrastructure, private healthcare providers will continue to boost their market share.

Private hospitals will benefit from the long-term increase in household earnings because a sizable portion of their revenue comes from out-of-pocket expenses. A Coordination of Benefits (COB) scheme will also present opportunities for private healthcare providers, which permits patients to increase their entitled benefits by obtaining additional health insurance coverage from Indonesia's universal healthcare system.

In Indonesia, breast cancer is the leading cause of mortality among females. Today, mammography is widely accepted and advised for the early diagnosis of breast cancer. Improved survival rates for breast cancer patients depend on early diagnosis and access to the best treatments. However, because of financial obstacles and a lack of healthcare resources, access to mammography is frequently prohibitive in many underdeveloped nations like Indonesia. Breast cancer stigma, a lack of biomedical treatment, and very low awareness of the disease are to blame for the majority of breast cancer deaths in developing nations like Indonesia. Breast cancer stigma and misunderstanding of screening procedures were found to be potential factors that prevented women with breast cancer symptoms from seeking medical attention.

indonesia breast cancer therapeutics market

Market Dynamics

Market Growth Drivers

The market for breast cancer therapeutics in Indonesia will expand as the prevalence of breast cancer increases. Growing research and development capabilities to experiment with breast cancer treatment technologies and offer newer pharmaceutical medications will also support the expansion of the breast cancer therapeutics industry in Indonesia. Increased public knowledge of potential surgical choices and treatment modalities will help the breast cancer drug market expand at a faster rate. The government of Indonesia is taking action to make things better, including increasing financing for cancer research and treatment and raising public awareness of the value of early detection which will lead to further market growth.

Market Restraints

Market expansion in Indonesia will be hampered by the high expense of undergoing surgical therapy. Therapeutic side effects will once more pose a threat to market expansion. The market growth rate will be hampered by the poor technology infrastructure in Indonesia. Furthermore, the government of Indonesia does not prioritize breast cancer because it is seen as a non-communicable disease.

Competitive Landscape

Key Players

Meiji Holdings (IDN)
Menarini (IDN)
Dexa Medica (IDN)
Sanbe Pharma (IDN)
Biocon
Merck & Co. Inc.
Genzyme Corporation
Janssen Global Services LLC
MacroGenics Inc.

Healthcare Policies and Regulatory Landscape

The National Health Insurance (JKN), Indonesia's national healthcare program, covers breast cancer treatment for its residents. Through the JKN, the government also offers financial support to persons with low incomes and those who have advanced stages of breast cancer. The "Pink Ribbon" campaign, an annual event to raise awareness about breast cancer, is only one of the efforts and activities that Indonesia has put in place to promote early identification and raise awareness about breast cancer.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.